These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33596679)

  • 21. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
    Gentile S
    Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP).
    Segarra R; Recio-Barbero M; Sáenz-Herrero M; Mentxaka O; Cabezas-Garduño J; Eguíluz JI; Callado LF
    Int J Neuropsychopharmacol; 2021 Sep; 24(9):694-702. PubMed ID: 34009370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies.
    Ostuzzi G; Bighelli I; So R; Furukawa TA; Barbui C
    Schizophr Res; 2017 May; 183():10-21. PubMed ID: 27866695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
    Meyer JM
    CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
    Majer IM; Gaughran F; Sapin C; Beillat M; Treur M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
    Lian L; Kim DD; Procyshyn RM; Cázares D; Honer WG; Barr AM
    PLoS One; 2022; 17(4):e0267808. PubMed ID: 35486616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Likhitsathian S; Suttajit S; Maneeton N; Maneeton B; Oon-Arom A; Suradom C
    Drug Alcohol Depend; 2021 Feb; 219():108467. PubMed ID: 33385693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
    Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
    Misawa F; Fujii Y; Takeuchi H
    J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35921512
    [No Abstract]   [Full Text] [Related]  

  • 38. Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.
    Theodoros T; Taylor M; Huang HC; Wang N; Motamarri B
    Australas Psychiatry; 2018 Jun; 26(3):303-306. PubMed ID: 29457473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
    Kishi T; Citrome L; Sakuma K; Iwata N
    Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.